Effects of flecainide on the electrophysiological properties of atrial vulnerability in humans.
The aims of this study were to evaluate the changes in the electrophysiological characteristics of the right atrium after the administration of flecainide and to clarify whether flecainide has a selective effect on human atrial tissue. Electrophysiological measurements were made in 38 patients, before and after intravenous administration of flecainide (2 mg/kg per 10 min). The effective refractory period of the right atrium (ERP-A), maximum conduction delay (Max.CD), repetitive atrial firing zone (RAFZ), fragmented atrial activity zone (FAAZ), and conduction delay zone (CDZ) were studied in the patients who were divided into 2 groups based on whether repetitive atrial firing (RAF) was induced in the baseline study. Flecainide significantly prolonged the ERP-A (202+/-22 to 238+/-33 ms, p<0.001) and shortened Max.CD (77+/-17 to 63+/-32 ms, p<0.05) in the patients with RAF, but not in those without RAF in the baseline study. After flecainide administration, there were significant reductions in the RAFZ (43+/-22 to 13+/-19 ms, p<0.0001), FAAZ (51+/-22 to 28+/-26 ms, p<0.001) and CDZ (70+/-21 to 48+/-30 ms, p<0.01) in the patients with RAF. However, atrial fibrillation (AF) was induced by stimulation after flecainide in 2 patients without RAF in the baseline study. There was a significant negative correlation between the ERP-A in the baseline study and the change in the ERP-A upon flecainide administration (r=0.45, p<0.01). Flecainide may preferentially activate the substrate for AF and RAF, but that action is mainly based on the electrophysiological characteristics found in the baseline study.
The Department of Medical Bioregulation, Faculty of Science, Yamaguchi University School of Medicine, Ube, Japan.
Yasuhiro
Y
Yoshiga
Akihiko
A
Shimizu
Toshihiko
T
Yamagata
Masahiro
M
Esato
Takeshi
T
Ueyama
Masato
M
Ohmura
Kazuo
K
Itagaki
Masayasu
M
Kimura
Hiroyuki
H
Kakugawa
Masahiro
M
Doi
Masunori
M
Matsuzaki
D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D004562:Electrocardiography; D004594:Electrophysiology / Q000379:methods; D005260:Female; D005424:Flecainide / Q000494:pharmacology*; D006325:Heart Atria / Q000187:drug effects / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis
D000889:Anti-Arrhythmia Agents; D005424:Flecainide